APCMV 2024

ASIA-PACIFIC CONGRESS OF MEDICAL VIROLOGY

19 - 21 NOVEMBER • Singapore EXPO

E-PROGRAMME



CATALYSED BY

TEMASEK FOUNDATION

Infectious Diseases Labs

DukeNUS Medical School | Emerging Infectious Diseases

SUPPORTED BY

Lee Kong Chian School of Medicine

NUS National University of Singapore

NUS National University of Singapore | Infectious Diseases Translational Research Programme Yong Loo Lin School of Medicine

SSMB

ORGANISED BY

MANAGED BY

KENES GROUP SINGAPORE

www.apcmv.com

TABLE OF CONTENTS

NAVIGATING THROUGH APCMV 2024



COMPANY NAME	BOOTH NO.
ABB	A01
GAIA SCIENCE PTE LTD	A02
GLOBAL COLD CHAIN SOLUTIONS	A03
PROMEGA	A04
VAYZME SINGAPORE	A05
YAKULT SINGAPORE PTE LTD	A06
MDPI	A07
SINGLAB TECHNOLOGIES	A08
TEMASEK FOUNDATION	A09
PRECISION TECHNOLOGIES	B01
EPPENDORF	B02
CORDX,INC.	B03

WELCOME MESSAGE
FROM THE APSMV PRESIDENT

It is with great excitement for me to welcome you to the restart of the Asia Pacific Congress of Medical Virology (APCMV) series in 2024. As the President of the Asia Pacific Society of Medical Virology, I would like to thank the organising committee of the APCMV 2024, and it is with great confidence that the restart of the congress series will be a success with the committee's tireless contribution. I would like to extend my heartiest welcome to all the delegates of APCMV 2024 to Singapore, and I hope you have a fruitful time here.

Thank you,

Justin Jang Hann Chu
President
Asia Pacific Society of Medical Virology

WELCOME MESSAGE FROM THE ORGANISING COMMITTEE

It is with great pleasure and anticipation that I welcome you to the Asia Pacific Congress of Medical Virology (APCMV) 2024. As the organiser of this prestigious scientific Congress, we are honored to bring together virologists in different aspects of research from the Asia Pacific region. We hope that this will be an exciting three days of sharing of the labor of our research, coming out of the COVID-19 pandemic that is a crucial litmus test of how prepared we are in doing what we are trained to do.

The past three years have been a testament to our unwavering commitment to humanity's protracted battle with viruses. In our pursuit for preparedness against disease X, we acknowledge the diverse backgrounds, experiences, and perspectives that each of you brings. It is this rapid sharing of information during the COVID-19 pandemic that drives the effort against the virus and the pandemic, and we hope that the same can be achieved with the APCMV congress series to enable the same essence of collaboration seen during the pandemic.

We have a selection of topics covering a wide spectrum of disciplines in virology research, ranging from basic to clinical and public health related research. We would like to see, via these topics, interactions, networking and discussions that drives the close collaboration in the region that can go on to become the core in the fight against medically important viruses, while developing lasting relationships that transcend geographical boundaries.

Thank you for your participation to breathe new life into the Congress series.

Warm regards,

Tan Kai Sen
Organising chairman
On behalf of the organising committee of
Asia Pacific Congress of Medical Virology

ABOUT APCMV

The Asia-Pacific Congress of Medical Virology (APCMV) is a triennial international meeting that focuses on diagnostic, public health, research, and clinical virology, with emphasis on the Asia Pacific region. The aim of this congress is to foster collaboration and information sharing of the latest research in the field of virology pertaining to medically important viruses and treatments against them.

Including the most recent COVID-19 pandemic, many emerging virus infections have been centered in the Asia Pacific region, and the breaking down of boundaries between civilization and wildlife only serves to accelerate that. Therefore, it is vital for the countries in the region to develop a strong public health, diagnostic and research base to address these problems. Hence the APCMV congress series was started to enable the review, sharing and discussion in each of these areas for forming a strong foundation against the management of medically important viruses.

ORGANISING SOCIETY

Asia Pacific Society of Medical Virology

The APSMV is a regional collective of the medical virology field dedicated to foster regional collaboration for the advancement in viral disease management. Established in year 1982, we aim to form a collaborative network of virologist in the region to enhance resource and information sharing of research in the field, to enhance the collective capacity in dealing with current and emerging viral infectious diseases within the region.

Our Mission: At the heart of our society's mission is the pursuit of knowledge, understanding, and translation of virology research from bench to bedside within the region. Hence, the society strives to:

Promote Scientific Excellence: To foster a culture of scientific excellence by providing platforms for researchers, scientists, and students to showcase their groundbreaking work in virology.

Knowledge Exchange: To facilitate the sharing and exchange of resources, knowledge and expertise among our members and the broader scientific community through conferences, publications, and networking.

Community Building: To cultivate a supportive and collaborative community of virologists from both basic and clinical disciplines, and to encourage networking and mentorship opportunities that benefit professionals at all stages of their careers.

Outreach and Education: To reach out to the public via education for raising awareness and literacy about viruses and their impact on human and environmental health.

Regional Advancement: To work closely with local and regional institutions, government bodies, and healthcare organizations to address virology challenges, enhance preparedness for emerging viral threats, and contribute to public health initiatives in the region.

The society hopes that with the strong regional ties developed within the medical virology community will help step up the research and outbreak preparedness capacity of the region, to deal with any emerging threats that may arise effectively.

SUPPORTING ORGANISATION

Singapore Society for Microbiology and Biotechnology

Established in 1972, the society received strong support from members of the academia as well as industry to promote research and development in the field of microbiology and biotechnology. With the rapid changes in research landscape, it is crucial that fellow microbiologists and biotechnologists keep abreast of developments in the field.

We hope to enhance the society as a networking platform to strengthen the exchange and sharing of microbiological knowledge. Society also endeavours to play a part in the advancement of microbiology and biotechnology through community engagement and education. Outreach efforts are focused to nurture the next generation of microbiologists and biotechnologists.

As we live with the new norm that the COVID-19 pandemic brings along, I sincerely hope that everyone will stay safe and continue to render support to SSMB so that we can work together to bring the Singapore Microbiology and Biotechnology scene to greater heights.

CATALYSED BY

TEMASEK FOUNDATION

SUPPORTED BY

Infectious Diseases Labs
ID LABS

DukeNUS Medical School | Emerging Infectious Diseases

LEE KONG CHIAN SCHOOL OF MEDICINE
NANYANG TECHNOLOGICAL UNIVERSITY SINGAPORE
Imperial College London

NUS National University of Singapore

NUS National University of Singapore | Infectious Diseases Translational Research Programme
Yong Loo Lin School of Medicine

Singapore Society for Microbiology and Biotechnology SSMB

ORGANISING COMMITTEE

Committee Chairman:

Dr Tan Kai Sen
National University of Singapore,
Singapore

Committee Members:

Dr Chia Po Ying
National Centre for Infectious Diseases,
Singapore

A/Prof Luo Dahai
Nanyang Technological University,
Singapore

Dr Mok Chee Keng
A*STAR Infectious Diseases Labs
(A*STAR IDL), Singapore

Dr Mookkan Prabakaran
Temasek Life Sciences Laboratory,
Singapore

Dr Ooi Yaw Shin
Duke-NUS Medical School,
Singapore

Dr Tan Chee Wah
National University of Singapore,
Singapore

ADVISORY BOARD MEMBERS

Prof Chu Jang Hann, Justin
Advisory Board Chair
National University of Singapore

Prof Benhur Lee
Icahn School of Medicine at Mount Sinai,

Prof Chan Yoke Fan
University of Malaya

Prof Chen Chun-Hong
National Institute of Infectious Diseases and Vaccinology

Prof Cheng Gong
Tsinghua University

Prof David Lye Chien Boon
National Centre for Infectious Diseases

Prof Fedik Abdul Rantam
Airlangga University

Prof Gavin Smith
Duke-NUS Medical School

Prof Huang Li-Min
National Taiwan University

Prof Jason Mackenzie
The University of Melbourne

Prof Kenny Voon Gah Leong
University of Nottingham Malaysia

Prof Leo Yee Sin
National Centre for Infectious Diseases

Prof Linfa Wang
Duke-NUS Medical School

Prof Lisa Ng
A*STAR Infectious Diseases Labs (A*STAR IDL), Singapore

Prof Malik Peiris
The University of Hong Kong

Prof Mariano Garcia-Blanco
University of Virgina

Prof Mohammad Bosaeed
King Abdullah International Medical Research Center (KAIMRC)

Prof Ng Lee Ching
Environmental Health Institute at National Environment Agency

Prof Paul Anantharajah Tambyah
National University Hospital

Prof Paul Kay Sheung Chan
The Chinese University of Hong Kong

Prof Prasert Auewarakul
Mahidol University

Prof Sharon Lewin
The University of Melbourne

Prof Shi Zhengli
Wuhan Institute of Virology

Prof Shiao Shin-Hong
National Taiwan University

Prof Shih Shin-Ru
Chang Gung University

Prof Stephen Kent
The University of Melbourne

Prof Stephen Thomas
Upstate Medical University

Prof Sujatha Sunil
International Centre for Genetic Engineering and Biotechnology

Prof Suresh Mahalingam
Griffith University

Prof Wang Jen-Ren
National Cheng Kung University

Prof. Wang Linfa
Duke-NUS Medical School

Prof Yu Hongjie
Fudan University

Prof Yuen Kwok-Yung
The University of Hong Kong

Prof Zhang Linqi
Tsinghua University

Prof Zhao Jincun
Guangzhou Medical University

Prof Zhou Xi
Wuhan Institute of Virology

GENERAL INFORMATION

Title	Asia-Pacific Congress of Medical Virology (APCMV 2024)
Date	19 - 21 November 2024
Venue	Singapore EXPO Meeting Rooms, Level 2 1 Expo Drive, #02-01, Singapore 486150
Website	www.apcmv.com
Internet Access	Complimentary WiFi is available within the Congress venue.
Language	The official language of the Congress is English. All presentations will be made in English.
Congress Managed By	Kenes MP Asia Pte Ltd 20 Kallang Avenue, PICO Creative Centre Level 2 Singapore 339411
Liability and Personal Insurance	The Congress Secretariat and organisers cannot accept liability for personal accidents or loss of/damage to private property of participants, either during or indirectly arising from the Congress. We recommend that all participants take out personal travel and health insurance for the trip.
Transportation	**By Train/MRT** MRT Lines: East-West (Green Line), Downtown (Blue Line) Nearest Station: Expo MRT Station (CG1/DT35) (Closest to Foyer Two and Hall 6). Meeting Rooms are approximately a 10-minute walk from Expo MRT station. **By Public Bus** Recommended Bus Stops: 96029: Bus services 12, 24, 38 96021 (Opposite EXPO): Bus services 12, 24, 38 **By Taxi** Taxi Stand: I42 **By Private-Hire Car** Services: ComfortDelGro, Gojek, Grab or TADA Drop-off Location: Singapore EXPO Max Atria/Hall 1 (Note: Fares may fluctuate based on demand)

REGISTRATION

Congress Badge

Please note that your congress badge is personal and non-transferable. You may collect your congress badge at the Delegate Registration Counters.

Name badges must be worn at all times for admittance to all APCMV 2024 programmes.

Kindly prepare your Confirmation Email/Registration ID for a fuss-free badge collection process.

Please refer to the below table for opening hours:

Date, Day	**Time (Singapore, GMT +8)**
19 November, Tuesday – Day 1	0800 – 1600
20 November, Wednesday – Day 2	0830 – 1600
21 November, Thursday – Day 3	0830 – 1600

Certificate of Attendance

Certificate of attendance will be sent via email 2 weeks after the Congress.

INVITED SPEAKERS

PLEASE CLICK HERE TO VIEW THE ABSTRACT PAPERS

Prof Derrick Heng
GUEST OF HONOUR
Deputy Director-General of Health (Public Health)
Ministry of Health, Singapore

Prof Benhur Lee
Icahn School of Medicine, Mount Sinai (ISMMS)

Dr Carolien Emma Van De Sandt
University of Melbourne

Dr Chia-Yu Chi
National Health Research Institutes

Prof Chih-Peng Chang
National Cheng Kung University

Dr Ching-Fen Shen
National Cheng Kung University Hospital

Prof David Lye Chien Boon
Society of Infectious Disease

Prof Eng Eong Ooi
Duke-NUS Medical School

Prof Gavin Smith
Duke-NUS Medical School

INVITED SPEAKERS

PLEASE CLICK HERE TO VIEW THE ABSTRACT PAPERS

Prof Guann-Yi Yu
National Health Research Institutes

Prof Hongjie Yu
Fudan University

Prof Horng, Jim-Tong
Chang Gung University

Prof Iskandar Azwa
University Malaya

Prof Jason Mackenzie
University of Melbourne

Prof Jen-Ren Wang
National Cheng Kung University

Prof Julian A. Hiscox
University of Liverpool

Prof Kei Sato
The University of Tokyo

Dr Le Thi Nguyet Minh
NUS Medicine Department of Pharmacology

Prof Leo Yee Sin
National Centre for Infectious Diseases and National Healthcare Group

INVITED SPEAKERS

PLEASE CLICK HERE TO VIEW THE ABSTRACT PAPERS

Ms Li-Jin Hsu
National Cheng Kung University

Prof Linfa Wang
Duke-NUS Medical School

Prof Marco Vignuzzi
*A*STAR Infectious Diseases Labs (A*STAR IDL)*

Mr Muhammad Bashir Bello
King Abdullah International Medical Research Center (KAIMRC)

Prof Peiris, Joseph Sriyal Malik
The University of Hong Kong

Prof Prasert Auewarakul
Faculty of Medicine Siriraj Hospital, Mahidol University

Prof Priscilla Li-ning Yang
Stanford University School of Medicine

Prof Shin-Hong Shiao
National Taiwan University

Prof Shin-Ru Shih
Chang Gung University

INVITED SPEAKERS

PLEASE CLICK HERE TO VIEW THE ABSTRACT PAPERS

Prof Stephen Kent
University of Melbourne

Prof Suresh Mahalingam
Griffith University

Mr Takeshi Tanaka
Nagasaki University Hospital

Dr Tetsuji Hori
Yakult Honsha Co., Ltd.

Dr Tzong-Shiann Ho
National Cheng Kung University

Prof Veasna Duong
Institut Pasteur du Cambodge

Prof Yoke-Fun Chan
University of Malaya

Prof Zhang Linqi
Tsinghua University

Prof Zhengli Shi
Wuhan Institute of Virology, Chinese Academy of Sciences and the Group Leader for Emerging Viruses

PROGRAMME

DAY 1 | 19 NOVEMBER 2024, TUESDAY

Time	Peridot 201 - 203	Peridot 205 - 206
0800 Onwards	**Registration**	
0830 - 0900	**Welcome Addresses** *APCMV Organising Chair, Dr Tan Kai Sen, National University of Singapore, Singapore* *Asia Pacific Society of Medical Virology (APSMV) President, Prof Justin Jang Hann Chu, Singapore* *Guest of Honour Prof Derrick Heng, Ministry of Health, Singapore* *Peridot 201 - 203*	
0900 - 1000	**Chan Yow Cheong Memorial Lecture: Pandemic Preparedness** *Prof Peiris, Joseph Sriyal Malik, The University of Hong Kong, Hong Kong SAR* *Moderated by: Prof Linfa Wang, Duke-NUS Medical School, Singapore* *Peridot 201 - 203*	
1010 - 1120	**Symposium 1:** **Emerging and Zoonotic Infections** *Moderated by: Prof Marco Vignuzzi* *A*STAR Infectious Diseases Labs (A*STAR IDL), Singapore*	**Symposium 2:** **Influenza and Other Respiratory Viruses 1** *Moderated by: A/Prof Vincent Chow* *National University of Singapore, Singapore*
1010 - 1040	**Can We Develop A "Dream" Vaccine Against Coronaviruses?** *Prof Linfa Wang* *Duke-NUS Medical School, Singapore*	**Long COVID: Epidemiology, Pathogenesis and Treatment** *Prof David Lye Chien Boon, National Centre for Infectious Diseases, Singapore*
1040 - 1050	**Are Antigen-Specific Vaccines Sufficient to Prevent Future Pandemics?** *Dr Tan Chee Wah* *National University of Singapore, Singapore*	**Seasonal Influenza Vaccination for Children: A Cost-Effectiveness Analysis of Cell-Based versus Egg-Based Influenza Vaccine in Taiwan** *Dr Chia-Yu Chi* *National Health Research Institutes, Taiwan*
1050 - 1100	**Genetic Dissection of Virus-Host Interactions in Bat Cells** *Dr Kam Leng Aw Yong* *Duke-NUS Medical School, Singapore*	
1100 - 1110	**Severe Fever with Thrombocytopenia Syndrome (SFTS) Virus Infection: A Life-threatening Infection in Asia, A Perspective from Japan** *Prof Takeshi Tanaka* *Nagasaki University Hospital, Japan*	**Enhanced Virulence and Pathogenicity of Influenza B/Victoria Virus by Combined Haemagglutinin Mutations in Mice** *Giselle GK Ng* *Duke-NUS Medical School, Singapore*
1110 - 1120	**ERINHA's Contribution to Global Pandemic Preparedness and Response Research** *Dr Diana Stepanyan* *ERINHA, Belgium*	**Effect of Variation in Fusion Protein of Predominant Respiratory Syncytial Virus Genotypes on Viral Replication, Pathogenicity, and Antibody Susceptibility** *Dr Jingjing Song* *National University of Singapore, Singapore*
1120 - 1140	Coffee/Tea break, Exhibition & Posters viewing Temasek Foundation's Talk at Temasek Foundation Booth (1120 - 1135)	

PROGRAMME

DAY 1 | 19 NOVEMBER 2024, TUESDAY

Time	Peridot 201 - 203	Peridot 205 - 206
1140 - 1250	**Symposium 3:** **Influenza and Other Respiratory Viruses 2** *Moderated by: Dr Ooi Yaw Shin* *Duke-NUS Medical School, Singapore*	**Symposium 4:** **Viral Diagnostic** *Moderated by: Dr Mok Chee Keng* *A*STAR Infectious Diseases Labs* *(A*STAR IDL), Singapore*
1140 - 1210	**Environmental Surveillance for Zoonotic Viruses in Live-bird Markets** *Prof Gavin James Smith* *Duke-NUS Medical School, Singapore*	**Using AI/ML Approaches to Predict the Outcome of Infection in Ebola Virus and SARS-CoV-2 and Future Viral Evolution to Better Inform Medical Countermeasures** *Prof Julian A. Hiscox* *University of Liverpool, United Kingdom*
1210 - 1220	**Identification of Residues in MERS-CoV Spike Receptor Binding Domain Implicated in Viral Entry and Immune Evasion** *Rachael Dempsey* *University of Liverpool, United Kingdom*	**Evaluation and Comparison of Three High Throughput Assays (Abbott Alinity M, Hologic Aptima CMV Quant and Roche Cobas) for Quantifying CMV DNA in Plasma Samples** *Jodie D'Costa* *Victorian Infectious Diseases Reference Laboratory at the Peter Doherty Institute for Infection and Immunity, Australia*
1220 - 1230	**Human Parainfluenza Virus 3 Infection Elicits a Glycolytic Shift and Inflammatory Response in Human Nasal Epithelial Ciliated and Goblet Cells** *Dr Alan Hsu* *Duke-NUS Medical School, Singapore*	**The Utility of Non-Molecular Diagnostic Tests for Common Herpesviruses in the Clinical Setting, A Tertiary Hospital Lab's Perspective in Singapore** *Dr Wan Wei Yee* *SingHealth, Singapore*
1230 - 1240	**Epithelial Responses to H5N1 Influenza Infection in An Influenza Airway Infection Model** *Dr Tan Kai Sen* *National University of Singapore, Singapore*	**An Integrated Droplet Microfluidic Platform Capable of High-Throughput Functional Mab Screening** *Ajayanandan Yadunan* *A*STAR Infectious Diseases Labs* *(A*STAR IDL), Singapore*
1240 - 1250	**High-Yield Novel Chimeric Seasonal Influenza Virus-Like Particles (VLPs) Induced Potent Immune Responses and Protected Mice from Lethal Virus Challenges** **A T M Badruzzaman** *National Health Research Institutes (NHRI) and National Central University (NCU), Taiwan*	**Structural and Functional Insights of Dengue Virus Non-Structural Protein 1 (NS1) in Disease Pathogenesis** *Chan Wing Ki Kitti* *Duke-NUS Medical School, Singapore*
1250 - 1415	Lunch, Exhibition & Posters viewing	

PROGRAMME

DAY 1 | 19 NOVEMBER 2024, TUESDAY

Time	Peridot 201 - 203	Peridot 205 - 206
1415 - 1525	**Symposium 5: Enteroviruses** *Moderated by: Prof Jen-Ren Wang* *National Cheng Kung University, Taiwan*	**Symposium 6: Transformative Technologies in Virus Research 1** *Moderated by: Prof Julian A. Hiscox* *University of Liverpool, United Kingdom*
1415 - 1445	**Serological Perspectives on HFMD Vaccine Strategy: A Population-Based Study of EV-A71 and CVA16 in Chinese Children** *Prof Hongjie Yu* *Fudan University, China*	**Potential Applications of Extracellular Vesicles as Anti-viral Agents and Carriers of Anti-viral Antisense Oligonucleotides** *Dr Le Thi Nguyet Minh* *National University of Singapore, Singapore*
1445 - 1455 1455 - 1505	**Enterovirus A71 and Coxsackievirus A16: Friend or Foe?** *Prof Yoke-Fun Chan* *Universiti Malaya, Malaysia*	**Unraveling the Dynamics of Dengue: Integrating Antibody Profiling and Machine Learning for Enhanced Diagnosis and Severity Prediction** *Dr Tzong-Shiann Ho* *National Cheng Kung University, Taiwan*
1505 - 1515	**Multi-Omics Dissection Enterovirus-D68 Disease Pathogenesis for Identification of Novel Antiviral Therapeutics** *Kalam Nida* *Monash University Malaysia* *Malaysia*	**Understanding the Enhanced Immune Responses to High-Density Microarray Patch Vaccination through Spatial Transcriptomics and Antibody Repertoire Analysis** *A/Prof David Muller* *University of Queensland, Australia*
1515 - 1525	**mRNA Vaccine Expressing Virus-Like Particles of Enterovirus D68 Induces Potent Neutralising Antibodies and Protects Against Infection** *Yuta Kunishima* *The Research Foundation for Microbial Diseases of Osaka University, Japan*	**Engineering Antiviral Immune-Like Systems for Autonomous Virus Detection and Inhibition in Mice** *Dr Yidan Wang* *National University of Singapore, Singapore*
1525 - 1600	Coffee/Tea break, Exhibition & Posters viewing	
1600 - 1700	**Keynote 1: Emerging Infection** *Prof Zhengli Shi, Wuhan Institute of Virology, China* *Moderated by: Prof Justin Jang Hann Chu, National University of Singapore, Singapore* *Peridot 201 - 203*	
1815 - 1930	**APCMV Speakers' Appreciation Dinner** *(By Invite Only)* *Peridot 204*	

PROGRAMME

DAY 2 | 20 NOVEMBER 2024, WEDNESDAY

Time	Peridot 201 - 203	Peridot 205 - 206
0830 Onwards	**Registration**	
0900 - 1000	**Keynote 2:** **Virus Surveillance and Public Health Intervention** *Prof Leo Yee Sin* *National Centre for Infectious Diseases, Singapore* *Moderated by: Prof Suresh Mahalingam, Griffith University, Australia* *Peridot 201 - 203*	
1010 - 1120	**Symposium 7:** **Innovations in Vaccine Research 1** *Moderated by: Prof Zhang Linqi* *Tsinghua University, China*	**Symposium 8:** **Viral Pathogenesis** *Moderated by: Prof Jason Mackenzie* *University of Melbourne, Australia*
1010 - 1040	**COVID-19 Vaccines: Timing, Protection and Off-target Effects** *Prof Stephen Kent* *University of Melbourne, Australia*	**Role of Internal Ribosomal Entry Site-Driven Translation on Neurovirulence of Picornaviruses** *Prof Shin-Ru Shih* *Chang Gung University, Taiwan*
1040 - 1050	**Systems Vaccinology of the BNT162b2 mRNA Vaccination in Healthy and Type 1 Diabetes Teenagers** *A/Prof Ching-Fen Shen* *National Cheng Kung University, Taiwan*	**Overlying Particle Deposition Patterns onto Viral Receptor Distributions May Indicate Potential Spectrum of Clinical Disease Severity for Novel Airborne Respiratory Virus Infections** *Dr Julian Wei-Tze Tang* *University Hospitals of Leicester NHS Trust, United Kingdom*
1050 - 1100		**Cross-Species Evolution of IFITM3 Antiviral Function** *Dr Aaron Irving* *Zhejiang University School of Medicine, China*
1100 - 1110	**Flavivirus Genome Recoding is a Broad-Spectrum Vaccine Technology for Constructing Live Attenuated Vaccine Strains for Both the Aedes and Culex Clade Mosquito-Borne Orthoflaviviruses** *Dr Wei-Xin Chin* *National University of Singapore, Singapore*	**SARS-CoV-2 ORF3a and Exosomes Mediate Distal Organ Dysfunction in COVID-19** *Dr Liang Qiming* *Shanghai Jiao Tong University School of Medicine, China*
1110 - 1120	**A Novel Self-Amplifying RNA Vaccine Vector based on Rubella Virus for RNA Vaccine Development against Infectious Diseases and Cancers** *Jing Miao* *Nanyang Technological University, Singapore*	**Mechanical Transmission of Dengue Virus by Aedes Aegypti May Influence Disease Transmission Dynamics** *Dr Chen Chun-Hong* *National Health Research Institutes, Taiwan*
1120 - 1140	Coffee/Tea break, Exhibition & Posters viewing	

PROGRAMME

DAY 2 | 20 NOVEMBER 2024, WEDNESDAY

Time	Peridot 201 - 203	Peridot 205 - 206
1140 - 1250	**Symposium 9:** **Innovations in Vaccine Research 2** *Moderated by: Prof Tan Chee Wah* *National University of Singapore, Singapore*	**Symposium 10** **Blood Borne Viruses** *Moderated by: Dr Chia Po Ying* *National Center for Infectious Diseases, Singapore*
1140 - 1210	**Human Antibody Response to SARS-CoV-1 and SARS-CoV-2: Implication for the Development of Next-Generation Antibody Drugs and Vaccines** *Prof Zhang Linqi* *Tsinghua University, China*	**Updates in HIV Prevention** *Prof Raja Iskandar Azwa* *Universiti Malaya Medical Centre, Malaysia*
1210 - 1220	**Effector Memory T Cells Induced After Prime/Boost Vaccination with Cytomegalovirus Vectors Against Conserved Influenza A Virus Antigens Protect Cynomolgus Macaques from Lethal, Aerosolised, Heterologous Challenge** *Dr Daniel Malouli* *Oregon Health & Science University, United States*	**Activation of BMP Signaling is Essential for Efficient Hepatitis B Virus Replication and Leads to Association of Smad1/5 With Viral cccDNA Minichromosome in the Nucleus** *Prof Tan Yee Joo* *National University of Singapore, Singapore*
1220 - 1230	**Evaluation of Dengue Immunity of Subjects in Singapore 5 Years Post-Third Dose of Dengvaxia Vaccine Using FcVR-Expressing Cells** *A/Prof Helen Oh* *Chang General Hospital, Singapore*	**PRMT3, A Novel Target for Anti-HIV-1 Infections** *A/Prof Yu Dan* *Beijing Children's Hospital, China*
1230 - 1240	**A Dendritic Cell-Targeting Approach to Deliver A Universal Influenza Vaccine Candidate to The Respiratory Mucosa** *Daryl Lee* *National University of Singapore, Singapore*	**Anti-HIV/HBV Drug Discovery: Our Exploration and Progress** *Prof Peng Zhan* *Shandong University, China*
1240 - 1250	**Next-Generation Vaccines: Genome Recoded Zika virus Live Attenuated Vaccine Induces Sterilising Immunity and Maternal-Fetal Protection** *Aw Zhen Qin* *National University of Singapore, Singapore*	**Occult Hepatitis C Infection: Evaluation of Risk to Transfusion Safety** *Prof Robert Flower* *Australian Red Cross Lifeblood, Australia*
1250 - 1415	Lunch break, Exhibition & Posters viewing	

PROGRAMME

DAY 2 | 20 NOVEMBER 2024, WEDNESDAY

Time	Peridot 201 - 203	Peridot 205 - 206
1415 - 1525	**Symposium 11:** **Prevention and Control of Viral Infections** *Moderated by: Prof Prasert Auewarakul* *Mahidol University* *Thailand*	**Symposium 12:** **Transformative Technologies in Virus Research 2** *Moderated by: Dr Carolien Emma van de Sandt* *The Peter Doherty Institute at the University of Melbourne, Australia*
1415 - 1445	**Future-Proofing Pandemic Response: Bridging Scientific Gaps with Mucosal Vaccines and Lessons from a Live Attenuated COVID-19 Vaccine** *Prof Suresh Mahalingam* *Griffith University, Australia*	**Defective Viral Genomes as RNA Vaccines and Therapeutics** *Prof Marco Vignuzzi* *A*STAR Infectious Diseases Labs (A*STAR IDL), Singapore*
1445 - 1455	**Antiviral Activity of Anisomycin Against Chikungunya Virus** *Dr Youichi Suzuki* *Osaka Medical and Pharmaceutical University, Japan*	**Using Epidemiological Findings to Efficiently Prevent and Control Epidemics of Major Viral Diseases in Taiwan: Implications for the Global Control of COVID-19** *Dr Chwan-Chuen King* *Institute of Epidemiology, Taiwan*
1455 - 1505	**Investigation of The Cellular Interactome of the Nucleocapsid Protein of Human Coronaviruses to Identify Potential Therapeutic Targets** *Ms Bobbie-Anne Turner* *University of Liverpool, United Kingdom*	**S2 Antibody Mapping Utilising a Deep Mutational Scanning Approach** *Dr Weikang Nicholas Lin* *A*STAR Infectious Diseases Labs (A*STAR IDL), Singapore*
1505 - 1515	**Unveiling the Robust Antiviral Action of MARVAS26 Against Picornaviruses Through Enteroviral VP1 and Sequestosome-1 Signaling** *Dr Thinesshwary Yogarajah* *National University of Singapore, Singapore*	**Utilising Experimental Human Dengue Virus Infection Models to Advance Vaccine Development** *Prof Stephen Thomas* *SUNY Upstate Medical University, United States*
1515 - 1525	**Development of Novel ANTI-HBV Agents: Characterisation of the N-Hydroxypyridine-diones (HPDs) as HBV RNASE H Inhibitors** *Prof Grigoris Zoidis* *National and Kapodistrian University of Athens, Greece*	
1525 - 1630	Coffee/Tea break, Exhibition & Posters viewing, Temasek Foundation Pandemic Preparedness ASEAN Forum	
1630 - 1730	**Keynote 3: Prevention and Control of Viral Infections** *Prof Kei Sato, The University of Tokyo, Japan* *Moderated by: Prof David Lye Chien Boon, National Centre for Infectious Diseases, Singapore* *Peridot 201 - 203*	

PROGRAMME

DAY 3 | 21 NOVEMBER 2024, THURSDAY

Time	Peridot 201 - 203	Peridot 205 - 206
0830 Onwards	**Registration**	
0900 - 1000	**Keynote 4:** **Pathogenesis and Immunology** *Prof Benhur Lee, Icahn School of Medicine at Mount Sinai, United States* *Moderated by: Prof Stephen Kent, University of Melbourne, Australia* *Peridot 201 - 203*	
1010 - 1120	**Symposium 13:** **Pathogenesis and Immunology** *Moderated by: Prof Shin-Ru Shih* *Chang Gung University, Taiwan*	**Symposium 14:** **Vector Borne Viruses 1** *Moderated by: Prof Eng Eong Ooi* *Duke-NUS Medical School, Singapore*
1010 - 1040	**Dynamics of CD8+ T Cell Immunity to Circulating and Pandemic Viruses** *Dr Carolien Emma van de Sandt* *The Peter Doherty Institute at the University of Melbourne, Australia*	**Antiviral for Dengue and Other Viruses** *Prof Prasert Auewarakul* *Mahidol University, Thailand*
1040 - 1050	**Antagonism of the cGAS-STING Mediated Antiviral Innate Immune Responses by SARS-CoV-2 Nsp15** *Dr Hsin-Ping Chiu* *Icahn School of Medicine at Mount Sinai, United States*	**Evolutionary Dynamics of Dengue Virus in Saudi Arabia and the Quest for Safe and Effective Vaccines** *Dr Muhammad Bashir Bello* *King Abdullah International Medical Research Center (KAIMRC), Saudi Arabia*
1050 - 1100	**Longitudinal Analysis of Virus-Specific Memory T Cells in the Nasal Mucosa** *Sabrina Ottolini* *Duke NUS Medical School, Singapore*	
1100 - 1110	**Structural Basis of Biased T Cell Recognition of Immune-Dominant Epitope of SARS-CoV-2 Spike Protein** *Dr Priyanka Chaurasia* *Monash University, Australia*	**Revealing the Intracellular Trafficking of Dengue Virus RNA Genome** *A/Prof Ping Yueh-Hsin* *National Yang Ming Chiao Tung University, Taiwan*
1110 - 1120	**Sexual Dimorphism Analysis Demonstrates Chemokine C-C Motif Ligand 2 Involvement in Enterovirus A71 Infection Pathogenesis** *Dr Huang Peng-Nien* *Chang Gung University, Taiwan*	**Clinical Challenges in Dengue** *Dr Chia Po Ying* *National Center for Infectious Diseases, Singapore*
1120 - 1140	Coffee/Tea break, Exhibition & Posters viewing Temasek Foundation's Talk at Temasek Foundation Booth (1120 - 1135)	

PROGRAMME

DAY 3 | 21 NOVEMBER 2024, THURSDAY

Time	Peridot 201 - 203	Peridot 205 - 206
1140 - 1250	**Symposium 15** **Host Pathogen Interaction** *Moderated by: Dr Kai Sen Tan* *National University of Singapore, Singapore*	**Symposium 16: Vector Borne Viruses 2** *Moderated by: Prof Stephen Thomas* *SUNY Upstate Medical University, United States*
1140 - 1210	**Small Molecule-directed Protein Degradation As An Antiviral Strategy** *Prof Priscilla Li-ning Yang* *Stanford University, United States*	**Dengue Pathogenesis - Beyond Antibody-dependent Enhancement** *Prof Eng Eong Ooi* *Duke-NUS Medical School, Singapore*
1210 - 1220	**Antiviral Effect of Probiotics including Lacticaseibacillus Paracasei Strain Shirota** *Dr Tetsuji Hori* *Yakult Honsha Co., Ltd., Japan*	**Two-Phase Interactome Analysis of Nucleocapsid Protein of Crimean-Congo Hemorrhagic Fever Virus and Human Proteins** *Dr Hirotaka Takahashi* *Ehime University, Japan*
1220 - 1230		**Genetic Analysis of Chikungunya Virus in Singapore in 2008-2024** *Dr Grace Ngan* *National Centre for Infectious Diseases, Singapore*
1230 - 1240	**Investigating the Roles of Plasminogen in Enterovirus A71 Infection** *Prof Chang Chuan-Fa* *National Cheng Kung University, Taiwan*	**Low-Density Lipoprotein Receptor (LDLR) is Key Receptor of Crimean Congo Hemorrhagic Fever Virus** *Prof Ali Mirazimi* *SVA, Sweden*
1240 - 1250	**Molecular Architecture of Coronavirus Double Membrane Vesicle Pore Complex** *Dr Ni Tao* *The University of Hong Kong, Hong Kong SAR*	**Chikungunya Virus (CHIKV) Infection During Pregnancy and Transplacental Transmission of CHIKV-Specific Antibodies** *Miss Xinyi Anna Loo* *A*STAR Infectious Diseases Labs (A*STAR IDL), Singapore*
1250 - 1415	Lunch, Exhibition & Posters viewing Temasek Foundation's Talk at Temasek Foundation Booth (1330 - 1345)	

PROGRAMME

DAY 3 | 21 NOVEMBER 2024, THURSDAY

<table>
<tr><th>Time</th><th>Peridot 201 - 203</th><th colspan="2">Peridot 205 - 206</th></tr>
<tr><td>1415 - 1525</td><td>Symposium 17:
Water and Food Borne Viruses
Moderated by: Prof Veasna Duong
Institut Pasteur du Cambodge, Cambodia</td><td colspan="2">Virology Joint Satellite Symposium by the Taiwan Society of Virology and Vaccinology and National Cheng Kung University</td></tr>
<tr><td>1415 - 1445</td><td rowspan="2">Norovirus: Translation, Termination and Transmission
Prof Jason Mackenzie
University of Melbourne, Australia</td><td colspan="2" rowspan="2">Enterovirus
Moderated by: Prof Shin-Ru Shih
Chang Gung University, Taiwan</td></tr>
<tr><td>1445 - 1455</td></tr>
<tr><td>1455 - 1505</td><td>Advancing Enterovirus Surveillance in Singapore: Insights from Molecular Genotypic Characterisation
Dr Daniel Lim
National Public Health Laboratory, Singapore</td><td>1415 - 1435</td><td>Disruption of Calcium Homeostasis as an Inhibitory Mechanism for Enterovirus D68 Replication
Prof Jim-Tong Horng
Chang Gung University, Taiwan</td></tr>
<tr><td>1505 - 1515</td><td>Investigating Human Circovirus (HcirV) Infection In Hong Kong
Wu ShuSheng
The University of Hong Kong, Hong Kong SAR</td><td>1435 - 1455</td><td>Effect of Genetic Variations of Enterovirus A71 on Viral Properties and Pathogenesis
Prof Jen-Ren Wang
National Cheng Kung University, Taiwan</td></tr>
<tr><td>1515 - 1525</td><td>Uncommon G3P[10] Rotavirus Strains Detected in Paediatric Patients with Acute Gastroenteritis in Thailand
Nutthawadee Jampanil
Chiangmai University, Thailand</td><td>1455 - 1515</td><td>Mechanistic Insight into WWOX-Mediated Suppression of Enterovirus Infection
Prof Li-Jin Hsu
National Cheng Kung University, Taiwan</td></tr>
<tr><td></td><td>A Novel Attenuated Enterovirus A71 Mutant with VP1-V238A, K244R Exhibits Reduced Efficiency of Cell Entry/Exit and Augmented Binding Affinity to Sulfated Glycans
Dr Tao Meng
Temasek Lifesciences Laboratory, Singapore</td><td colspan="2"></td></tr>
<tr><td>1525 - 1600</td><td colspan="3">Coffee/Tea break, Exhibition & Posters viewing</td></tr>
</table>

PROGRAMME

DAY 3 | 21 NOVEMBER 2024, THURSDAY

Time	Peridot 201 - 203	Peridot 205 - 206
1600 - 1710	**Symposium 18: Other Virus Infections of Medical Significance** *Moderated by: Dr Mookkan Prabakaran* *Temasek Life Sciences Laboratory, Singapore*	**Virology Joint Satellite Symposium by the Taiwan Society of Virology and Vaccinology and National Cheng Kung University** **Dengue Virus** *Moderated by: Prof Jen-Ren Wang* *National Cheng Kung University, Taiwan*
1600 - 1630	**Detection of Emerging Pathogens in Wildlife in Cambodia** *Prof Veasna Duong* *Institut Pasteur du Cambodge, Cambodia*	**1600 - 1620** **The Critical Role of Integrin Linked Kinase in Innate Responses to Dengue Virus Infection** *Prof Chih-Peng Chang* *National Cheng Kung University, Taiwan*
1630 - 1640	**SARS-CoV-2 and Ebola Virus Share Niemann-Pick C1 (NPC1)** *Prof Zheng Yong-Hui* *University of Illinois Chicago, United States*	**1620 - 1640** **Enhanced Pathogenicity and Transmissibility of Dengue Virus Strains** *Prof Guann-Yi Yu* *National Health Research Institutes, Taiwan*
1640 - 1650	**Hospitalisation Disease Burden of Varicella-Zoster Virus Infection in Post-Transplantation Pediatrics in China: The Imperative for Active Immunisation in Immunosuppressed Pediatric Populations** *Prof Ying Liu* *China*	**1640 - 1700** **Uncovering Dengue Virus Host Factors: Paving the Way for Innovative Antiviral Strategies** *Prof Shin-Hong Shiao* *National Taiwan University, Taiwan*
1650 - 1700	**Sialoglycotope-Dependent Entry of Paramyxoviruses Analysed by Cell-Based Glycan Arrays** *Wu Xuesheng* *Utrecht University, Netherlands*	
1700 - 1710	**Adaptive Metagenomic Sequencing Workflow for Accurate Near-Complete Reconstruction of Novel Viral Genomes** *Dr Chayaporn Suphavilai* *Genome Institute of Singapore, Singapore*	
1710 - 1725	**Awards & Closing Ceremony** *Peridot 201 - 203*	

DISCLAIMER: The programme is subject to change. Accurate at time of publishing.

TEMASEK FOUNDATION PANDEMIC PREPAREDNESS SERIES

TEMASEK FOUNDATION

BUILDING AN ASEAN NETWORK OF PROFESSIONALS IN MEDICAL VIROLOGY AND PANDEMIC PREPAREDNESS

DAY 1 | 19 NOVEMBER 2024, TUESDAY

Time	Temasek Foundation Booth
1120 - 1135	**Pandemic Preparedness and One Health Policies in Singapore** *Prof Derrick Heng* *Deputy Director of Medical Services* *Ministry of Health (MOH)* *Singapore*

DAY 2 | 20 NOVEMBER 2024, WEDNESDAY

Time	Temasek Foundation Booth
1525 - 1630	**Temasek Foundation Pandemic Preparedness ASEAN Forum**
1525 – 1530	**Opening Remarks** *Dr Lee Fook Kay* *Head, Pandemic Preparedness* *Temasek Foundation, Singapore*
1530 – 1620	**Dialogue** *Panellists:* *Dr Maria Endang Sumiwi, MPH* *Director General of Public Health* *Ministry of Health* *Indonesia* *Prof Dr Sazaly bin Abu Bakar* *Executive Director* *Tropical Infectious Diseases Research and Education Centre* *Malaysia* *Prof Derrick Heng* *Deputy Director of Medical Services* *Ministry of Health (MOH)* *Singapore* *Moderators:* *Prof Linfa Wang, Duke-NUS Medical School, Singapore* *Dr Lee Fook Kay, Temasek Foundation, Singapore*
1620 – 1630	**Closing Remarks** *Prof Linfa Wang* *Duke-NUS Medical School, Singapore*

TEMASEK FOUNDATION PANDEMIC PREPAREDNESS SERIES

TEMASEK FOUNDATION

BUILDING AN ASEAN NETWORK OF PROFESSIONALS IN MEDICAL VIROLOGY AND PANDEMIC PREPAREDNESS

DAY 3 | 21 NOVEMBER 2024, THURSDAY

Time	Temasek Foundation Booth
1120 - 1135	**Pandemic Preparedness and One Health Policies in Malaysia** *Prof Dr Sazaly bin Abu Bakar* *Executive Director* *Tropical Infectious Diseases Research and Education Centre* *Malaysia*
1330 - 1345	**Pandemic Preparedness and One Health Policies in Indonesia** *Dr Maria Endang Sumiwi, MPH* *Director General of Public Health* *Ministry of Health* *Indonesia*

ACCEPTED ORAL PRESENTATIONS

PLEASE CLICK HERE TO VIEW THE ACCEPTED ORAL ABSTRACT SUBMISSIONS

Abstract No.	Topic Title	Full Name
APCMVE001	Are Antigen-Specific Vaccines Sufficient to Prevent Future Pandemics?	Tan Chee Wah
APCMV1117	Genetic Dissection of Virus-Host Interactions in Bat Cells	Kam Leng Aw Yong
APCMVE002	ERINHA's Contribution to Global Pandemic Preparedness and Response Research	Diana Stepanyan
APCMV1262	Enhanced Virulence and Pathogenicity of Influenza B/Victoria Virus by Combined Haemagglutinin Mutations in Mice	Giselle GK Ng
APCMV1155	Effect of Variation in Fusion Protein of Predominant Respiratory Syncytial Virus Genotypes on Viral Replication, Pathogenicity, and Antibody Susceptibility	Jingjing Song
APCMV1065	Identification of Residues in MERS-CoV Spike Receptor Binding Domain That Are Implicated in Viral Entry and Immune Evasion	Rachael Dempsey
APCMV1072	Human Parainfluenza Virus 3 Infection Elicits a Glycolytic Shift and Inflammatory Response in Human Nasal Epithelial Ciliated and Goblet Cells	Alan Hsu
APCMV1156	Epithelial Responses to H5N1 Influenza Infection in an Influenza Airway Infection Model	Kai Sen Tan
APCMV1244	High-Yield Novel Chimeric Seasonal Influenza Virus-Like Particles (VLPs) Induced Potent Immune Responses and Protected Mice from Lethal Virus Challenges	A T M Badruzzaman
APCMV1012	Evaluation and Comparison of Three High Throughput Assays (Abbott Alinity m, Hologic Aptima CMV Quant and Roche cobas) for Quantifying CMV DNA in Plasma Samples	Jodie D'Costa
APCMV1034	The Utility of Non-Molecular Diagnostic Tests for Common Herpesviruses in the Clinical Setting, a Tertiary Hospital Lab's Perspective in Singapore	Wei Yee Wan
APCMV1113	An Integrated Droplet Microfluidic Platform Capable of High-Throughput Functional mAb Screening	Ajayanandan Yadunandan
APCMVE003	Structural and Functional Insights of Dengue Virus Non-Structural Protein 1 (NS1) in Disease Pathogenesis	Kitti Chan
APCMVE004	mRNA Vaccine Expressing Virus-Like Particles of Enterovirus D68 Induces Potent Neutralising Antibodies and Protects Against Infection	Yuta Kunishima
APCMV1176	Understanding the Enhanced Immune Responses to High-Density Microarray Patch Vaccination Through Spatial Transcriptomics and Antibody Repertoire Analysis	David Muller
APCMV1056	Engineering Antiviral Immune-Like Systems for Autonomous Virus Detection and Inhibition in Mice	Yidan Wang

ACCEPTED ORAL PRESENTATIONS

PLEASE CLICK HERE TO VIEW THE ACCEPTED ORAL ABSTRACT SUBMISSIONS

Abstract No.	Topic Title	Full Name
APCMV1228	Flavivirus Genome Recoding is a Broad-Spectrum Vaccine Technology for Constructing Live Attenuated Vaccine Strains for Both the Aedes and Culex Clade Mosquito-Borne Orthoflaviviruses	Wei-Xin Chin
APCMVE005	A Novel Self-Amplifying RNA Vaccine Vector Based on Rubella Virus for RNA Vaccine Development Against Infectious Diseases and Cancers	Jing Miao
APCMV1052	Overlying Particle Deposition Patterns onto Viral Receptor Distributions May Indicate the Potential Spectrum of Clinical Disease Severity for Novel Airborne Respiratory Virus Infections	Julian Wei-Tze Tang
APCMV1115	Cross-species Evolution of IFITM3 Antiviral Function	Aaron Irving
APCMV1111	SARS-CoV-2 ORF3a and Exosomes Mediate Distal Organ Dysfunction in COVID-19	Qiming Liang
APCMV1208	Mechanical Transmission of Dengue Virus by Aedes Aegypti May Influence Disease Transmission Dynamics	Chun-Hong Chen
APCMV1205	Effector Memory T Cells Induced after Prime/Boost Vaccination with Cytomegalovirus Vectors Against Conserved Influenza A Virus Antigens Protect Cynomolgus Macaques from Lethal, Aerosolized, Heterologous Challenge.	Daniel Malouli
APCMV1215	Evaluation of Dengue Immunity of Subjects in Singapore 5 Years Post-Third Dose of Dengvaxia Vaccine Using Fc R-expressing Cells	Helen Oh
APCMV1194	A Dendritic Cell-targeting Approach to Deliver a Universal Influenza Vaccine Candidate to the Respiratory Mucosa	Daryl Lee
APCMV1131	Next-Generation Vaccines: Genome Recoded Zika Virus Live Attenuated Vaccine Induces Sterilising Immunity and Maternal-Fetal Protection	Zhen Qin Aw
APCMV1083	Activation of BMP Signalling is Essential for Efficient Hepatitis B Virus Replication and Leads to Association of Smad1/5 with Viral cccDNA Minichromosome in the Nucleus	Tan Yee-Joo
APCMV1105	PRMT3, A Novel Target for Anti-HIV-1 Infections	Yu Dan
APCMVE014	Anti-HIV/HBV Drug Discovery: Our Exploration and Progress	Peng Zhan
APCMV1291	Occult Hepatitis C Infection: Evaluation of Risk to Transfusion Safety	Robert Flower
APCMV1230	Unveiling the Robust Antiviral Action of MARVAS26 Against Picornaviruses Through Enteroviral VP1 and Sequestosome-1 Signalling.	Thinesshwary Yogarajah
APCMV1161	Antiviral Activity of Anisomycin Against Chikungunya Virus	Youichi Suzuki
APCMV1070	Investigation of The Cellular Interactome of the Nucleocapsid Protein of Human Coronaviruses to Identify Potential Therapeutic Targets	Bobbie-Anne Turner

ACCEPTED ORAL PRESENTATIONS

PLEASE CLICK HERE TO VIEW THE ACCEPTED ORAL ABSTRACT SUBMISSIONS

Abstract No.	Topic Title	Full Name
APCMV1281	Development of Novel ANTI-HBV Agents: Characterisation of the N-Hydroxypyridinediones (HPDs) as HBV RNASE H Inhibitors	Grigoris Zoidis
APCMV1137	Using Epidemiological Findings to Efficiently Prevent and Control Epidemics of Major Viral Diseases in Taiwan: Implications for the Global Control of COVID-19	Chwan-Chuen King
APCMV1035	S2 Antibody Mapping Utilising a Deep Mutational Scanning Approach	Weikang Nicholas Lin
APCMV1133	Utilising Experimental Human Dengue Virus Infection Models to Advance Vaccine Development	Stephen Thomas
APCMV1058	Antagonism of the cGAS-STING Mediated Antiviral Innate Immune Responses by SARS-CoV-2 Nsp15	Hsin-Ping Chiu
APCMV1142	Longitudinal Analysis of Virus-Specific Memory T Cells in the Nasal Mucosa	Sabrina Ottolini
APCMV1088	Structural Basis of Biased T Cell Recognition of Immune-Dominant Epitope of SARS-CoV-2 Spike Protein	Priyanka Chaurasia
APCMV1126	Sexual Dimorphism Analysis Demonstrates Chemokine C–C Motif Ligand 2 Involvement in Enterovirus A71 Infection Pathogenesis	Peng-Nien Huang
APCMV1127	Multi-Omics Dissection Enterovirus-D68 Disease Pathogenesis for Identification of Novel Antiviral Therapeutics	Kalam Nida
APCMV1118	Revealing the Intracellular Trafficking of Dengue Virus RNA Genome	Yueh-Hsin Ping
APCMVE007	Clinical Challenges in Dengue	Chia Po Ying
APCMV1222	Investigating the Roles of Plasminogen in Enterovirus A71 Infection	Chuan-Fa Chang
APCMV1235	Molecular Architecture of Coronavirus Double Membrane Vesicle Pore Complex	Tao Ni
APCMV1172	Two-Phase Interactome Analysis of Nucleocapsid Protein of Crimean-Congo Hemorrhagic Fever Virus and Human Proteins	Hirotaka Takahashi
APCMV1055	Genetic Analysis of Chikungunya Virus in Singapore in 2008-2024	Grace Ngan
APCMV1154	Low-density Lipoprotein Receptor (LDLR) is the Key Receptor of Crimean Congo Hemorrhagic Fever Virus	Ali Mirazimi
APCMV1294	Chikungunya Virus (CHIKV) Infection During Pregnancy and Transplacental Transmission of CHIKV-Specific Antibodies	Xinyi Anna Loo
APCMV1063	Advancing Enterovirus Surveillance in Singapore: Insights from Molecular Genotypic Characterisation	Daniel Lim
APCMV1094	Investigating Human Circovirus (HcirV) Infection in Hong Kong	Shusheng Wu
APCMV1169	Uncommon G3P[10] Rotavirus Strains Detected in Paediatric Patients with Acute Gastroenteritis in Thailand	Nutthawadee Jampanil

ACCEPTED ORAL PRESENTATIONS

PLEASE CLICK HERE TO VIEW THE ACCEPTED ORAL ABSTRACT SUBMISSIONS

Abstract No.	Topic Title	Full Name
APCMV1238	A Novel Attenuated Enterovirus A71 Mutant with VP1-V238A, K244R Exhibits Reduced Efficiency of Cell Entry/Exit and Augmented Binding Affinity to Sulfated Glycans	Tao Meng
APCMVE008	SARS-CoV-2 and Ebola Virus Share Niemann-Pick C1 (NPC1)	Zheng Yong-Hui
APCMV1116	Hospitalisation Disease Burden of Varicella-Zoster Virus Infection in Post-Transplantation Paediatrics in China: The Imperative for Active Immunisation in Immunosuppressed Paediatric Populations	Ying Liu
APCMV1274	Sialoglycotope-Dependent Entry of Paramyxoviruses Analysed by Cell-Based Glycan Arrays	Wu Xuesheng
APCMV1221	Adaptive Metagenomic Sequencing Workflow for Accurate Near-Complete Reconstruction of Novel Viral Genomes	Chayaporn Suphavilai

POSTER PRESENTATIONS SCHEDULE

Date	Theme/Topic
19 November 2024, Tuesday	Emerging and Zoonotic Infections
19 November 2024, Tuesday	Influenza and Other Respiratory Viruses
19 November 2024, Tuesday	Innovations in Vaccine Research
20 November 2024, Wednesday	Host Pathogen Interaction
20 November 2024, Wednesday	Pathogenesis and Immunology
20 November 2024, Wednesday	Vector Borne Viruses
20 November 2024, Wednesday	Viral Diagnostics
21 November 2024, Thursday	Blood Borne Viruses
21 November 2024, Thursday	Other Virus Infections
21 November 2024, Thursday	Prevention and Control of Viral Infections
21 November 2024, Thursday	Virus Surveillance and Public Health Intervention

ACCEPTED POSTER PRESENTATIONS

PLEASE CLICK HERE TO VIEW THE ACCEPTED POSTER SUBMISSIONS

Abstract No.	Topic Title	Full Name
EMERGING AND ZOONOTIC INFECTIONS		
APCMV1009	Emerging and Zoonotic InfectionsBroadly Neutralising ACE2 Decoy as a Universal Coronavirus Therapeutic	Matthew Zirui Tay
APCMV1268	Genetic Diversity and Molecular Evolution of Hepatitis E Virus within the Genus Chirohepevirus in Bats	Bo Wang
APCMV1286	The Role of The Host Cell Microenvironment In MERS-Cov Infections	Tessa Prince
APCMV1288	Discovery of Porcine Deltacoronavirus in Cambodia between 2022-2024	Marcus Mah
APCMV1296	Mitigating Risk: Validated Inactivation Methods for Safe Mpox Sample Handling	Wei Lun Wong
INFLUENZA AND OTHER RESPIRATORY VIRUSES		
APCMV1016	Clinical Symptoms, Comorbidities and Health Outcomes Among Outpatients Infected with the Common Cold Coronaviruses Versus Influenza Virus in A Retrospective Cohort	Kok Keng Tee
APCMV1022	Epidemiology and Analysis of SARS-CoV-2 Omicron Subvariants BA.1 and 2 in Taiwan	Jih-Jin Tsai

ACCEPTED POSTER PRESENTATIONS

PLEASE CLICK HERE TO VIEW THE ACCEPTED POSTER SUBMISSIONS

Abstract No.	Topic Title	Full Name
APCMV1038	Impact of COVID-19 Restrictions on the Incidence of Respiratory Viruses in Two British Antarctic Survey Bases	Julian Wei-Tze Tang
APCMV1066	Time to Negative PCR Conversion Amongst COVID-19 Infected Cancer Patients at a Tertiary Care Hospital	Gaurav Salunke
APCMV1077	Production and Characterisation of Recombinant Neuraminidase of Different Influenza A Virus Subtypes for Serological Analysis and Monoclonal Antibody Generation	Kong Yen Liew
APCMV1079	Respiratory Syncytial Virus (RSV) Epidemiology in an Adult Tertiary Healthcare Setting in Singapore	Darius Yak Weng Chan
APCMV1081	Neutralisation of SARS-CoV-2 Omicron Subvariant by Antibodies Targeting Stem Helix Region in S2 Subunit of the Spike Protein	Yujia Cao
APCMV1085	Post-COVID Influenza Trends: A Comparative Analysis of Infection Rates and Transmission Patterns Among Community Adult and Dormitory Workers in Singapore	Benny Yeo
APCMV1090	Adenovirus Pneumonia and Disseminated Viremia in a Neonate Successfully Treated with Cidofovir and ECMO	Julian Wei-Tze Tang
APCMV1092	Changing Patterns of Seasonal Respiratory Virus Incidence (2018-2023) Pre- and Post-COVID-19, Leicester, UK	Julian Wei-Tze Tang
APCMV1136	Mutational Characterisation of Receptor Binding Domain in The Spike Proteins of the Omicron Variants Evading Vaccine Immunity in the Northeast Indian State of Tripura	Ankan Chakrabarti
APCMV1190	Development of Cellular Assays for the Comprehensive Analysis of Ferret Cytokine Responses	V. Stalin Raj
APCMV1200	Characterisation of an Air-Liquid Interface Bronchial Epithelial Model for Respiratory Viral Infections	Conrad En Zuo Chan
APCMV1245	Impact of Viral Co-Detection on Within-Host Viral Diversity of Influenza Patients	Su Myat Han
APCMV1256	The Co-Evolutionary Dynamics Between Wild-Type and Deletion-Containing Viral Genomes in Influenza Virus	Fadi Alnaji
APCMV1289	The Anti-Viral Role and Therapeutic Potential of Novel Seaweed-Derived Compounds	Daniele Mega
APCMV1282	Generation of Monoclonal Antibodies Against Human Parainfluenza Virus	Yvonne Su

INNOVATIONS IN VACCINE RESEARCH

APCMV1023	Vaccination With Live-Attenuated Salmonella-Based Vaccine Expressing PCV2d Cap and Rep as a Vaccination Strategy for Mucosal and Systemic Immune Responses Against PCV2d	John Hwa Lee

ACCEPTED POSTER PRESENTATIONS

PLEASE CLICK HERE TO VIEW THE ACCEPTED POSTER SUBMISSIONS

Abstract No.	Topic Title	Full Name
APCMV1024	Salmonella-Delivered COBRA-HA1 Antigen Derived from H1N1 Hemagglutinin Sequences Elicits Mucosal Immunity and Broad-Spectrum Protection Against Influenza A Subtypes	John Hwa Lee
APCMV1025	Development of SFTSV Vaccine Using an RNA Replicase Augmented Multigene Expression System Compatible Via Salmonella-Mediated Gene Delivery Platform to Induce Mucosal Immune Response	John Hwa Lee
APCMV1033	An Economical Adjuvant Without a Production Limit to Induce Potent Cell-Mediated Immunity in Subunit Vaccines	Cunbao Liu
APCMV1049	Immune Response To COVID-19 mRNA Vaccines in Adolescents with Type 1 Diabetes Mellitus: A Comparative Study with Healthy Controls	Shih-Wei Wang
APCMV1099	Identification of a Novel Antiviral Peptide Via Exploration of Protein Databases and Physicochemical Profiling	Minhyeong Lee
APCMV1107	Pandemic Preparedness: Understanding Coronavirus Spike-Receptor Interactions and Viral Entry for Improved Therapeutic and Vaccine Developments	V. Stalin Raj
APCMV1143	Superiority of Gamma-Irradiated Influenza A Vaccine Compared to Seasonal Flu Vaccine in Terms of Humoral Responses and Protective Efficacy	Mariana Couto Moniz
APCMV1144	Superior Immunity of Gamma-Irradiated NDV Vaccine Compared to Formalin-Inactivated Vaccine	Yimin Chuah
APCMV1148	Acute Oral Toxicity Assessment of Recombinant B. Subtilis Spores Expressing Dengue Virus NS1	Nurfatihah Zulkifli
APCMV1151	Recombinant Bacillus Subtilis Spores Expressing SARS-CoV-2 Spike Protein Induced Humoral, Mucosal and Cellular Immunity in Mice	Nurul Atiqah Nor Hazan
APCMV1174	Immunogenicity and Protective Efficacy of 3-in-1 Subunit DENV Vaccine in Diet-Induced Obese Mice	Shu-Wen Wan
APCMV1196	Targeting Clec9A on Type-I Conventional Dendritic Cells to Induce Broad and Durable Systemic and Mucosal Immune Responses Against SARS-CoV-2 and Sarbecoviruses	Nicholas Cheang
APCMV1199	Exploiting the Clec9A Targeting Vaccine Platform to Deliver a DENV Subunit Vaccine Candidate	Geraldine Nadya Putri
APCMV1232	The Role of Bacterial Vaginosis-Associated Bacteria in Trichomonas Vaginalis Adhesion and Pathogenicity in Multi-Species Biofilms	Shu-Fang Chiu
APCMV1240	Development of A Novel EV-A71 Monoclonal Antibody for Monitoring Vaccine Potency	Thi-Hong-Loc Le
APCMV1250	Deglycosylation of Influenza A H7N9 VLP Enhances Cross-Strain Neutralisation: Unveiling A Promising Vaccine Approach	Asmaul Husna

ACCEPTED POSTER PRESENTATIONS

PLEASE CLICK HERE TO VIEW THE ACCEPTED POSTER SUBMISSIONS

Abstract No.	Topic Title	Full Name
APCMV1284	Predicting Antibody Responses to COVID-19 Vaccines Using Host Factors	Hsiuyi Chen
HOST PATHOGEN INTERACTION		
APCMV1098	Immune Correlates with Disease Severity in Older Patients After SARS-Cov-2 BA.2 Infection in Hong Kong	Chen Bohao
APCMV1170	Integrin-Linked Kinase Enhances Enteroviral Infections	Li-Chiu Wang
APCMV1175	Rab37 Regulates Dengue Virus Attachment by Modulating Viral Entry Receptors on Host Cells	Wei-Chiao Liao
APCMV1183	The Impacts of the Crosstalk Between Bacterial Vaginosis Associated Bacteria and Trichomonas Vaginalis on the Pathogenesis and Host Immune Responses	Shu-Fang Chiu
APCMV1214	Impact of Variations Found in Quasispecies on Enterovirus A71 Viral Properties	Dayna Cheng
APCMV1224	Molecular Characterisation of Dengue Virus Strains from the 2023 Epidemic in Taiwan	Cheng-Fen Yang
APCMV1234	Identification of Potential Drug Targets of Itaconic Acid Derivatives with a Michael Acceptor Moiety Using Shotgun Proteomics	Hao-Wei Chu
APCMV1239	Down-Regulation of Serpin D1 (Heparin Cofactor II) Expression by Hepatitis C Virus	Chee Hing Yang
APCMV1249	Role of 14-3-3 Proteins in the Regulation of Influenza A Virus Replication	Rei-Lin Kuo
APCMV1254	High Throughput Protein Interaction Screen on Peptide Matrix to Identify Host Factors that Interact with SARS-CoV-2 Proteins	Amal Rahmeh
APCMV1285	Investigating the Entry Mechanisms of Human Coronavirus HKU1 Using Human Nasal Organoids	Julie Chu
APCMVE010	Biochemical Simulation of Mutation Synthesis and Repair During SARS-CoV-2 RNA Polymerisation	Adrian Oo
PATHOGENESIS AND IMMUNOLOGY		
APCMV1073	Influenza Virus Infection Instigates a Unique and Pathogenic ER Stress and Unfolded Protein Response in Human Nasal Epithelial Ciliated and Goblet Cells	Alan Hsu
APCMV1103	Species-Specific Viral Immunity Illuminated by Novel Horseshoe Bat Genomes	Yue Dong
APCMV1121	Association Of Δ42PD-1 Expression with Increased Regulatory B Cells in Hepatocellular Carcinoma	Ruomei Gong
APCMV1181	SARS-CoV-2 Immune Complexes Signal Through the FcγR Pathway and Activate the NLRP3 Inflammasome	Stefanie Fung

ACCEPTED POSTER PRESENTATIONS

PLEASE CLICK HERE TO VIEW THE ACCEPTED POSTER SUBMISSIONS

Abstract No.	Topic Title	Full Name
APCMV1187	Key Amino Acids in the Structural Envelope E Protein Drive the in Vivo Fitness and Virulence of DENV2 Cosmopolitan Strains Via Immune Evasion	Eunice Tan
APCMV1195	A Comparative Study of the Vaginal Microbiome of Women with Trichomonas Vaginalis, Chlamydia Trachomatis and Neisseria Gonorrhoeae	Shu-Fang Chiu
APCMV1218	Determination of Mucosal Immune Response Regions and the Development of Corresponding Assays for the Rapid Determination of Immune Status Against COVID-19 Utilising Saliva Samples	David Trudil
APCMV1236	Targeting Neutrophil Myeloperoxidase in Influenza Virus Infection	Andrew Teo
APCMV1243	Development of a Rapid Assay for the Evaluation of Pathogen-Specific T Cells in Human Samples	Anthony Tan
APCMV1292	Impact of Viral-Bacterial Co-Detection in Patients with Community-Acquired Pneumonia	Liang Hui Loo
VECTOR BORNE VIRUSES		
APCMV1047	Retrospective Laboratory Determination of Primary Versus Secondary Acute Dengue Infection, Characterisation Between A&E and Inpatient Admissions in a Single Healthcare Tertiary Centre in Singapore	Wei Yee Wan
APCMV1120	Evaluation of Yellow Fever Virus Serologic Assays for Diagnosis and Surveillance	Judith Chui Ching Wong
APCMV1184	The N153-Linked Glycans on Envelope Protein Protect the Dengue Virus from Antibody-Mediated Clearance	Donald Heng Rong Ting
APCMV1207	Unveiling The Agony: Chikungunya Fever Unleashing Severe Arthralgia	Hui Shan Chua
APCMV1225	The Combination of Remdesivir and Ivermectin Exerts Highly Potent and Synergistic Antiviral Activity Against Murine Coronavirus and SARS-CoV-2 Infections	Ryan Lew
APCMV1237	Neutrophil Mediators Linked to Tight Junction Disruption and Increased Intestinal Permeability in Severe Dengue	Andrew Teo
APCMV1251	Enhanced Production of Severe Fever with Thrombocytopenia Syndrome Virus Glycoprotein Virus-Like Particles Via Low-Temperature Incubation	Yi-Chin Fan
APCMV1271	Screening and Identification of Key Factors for Arbovirus Infection in Mosquito Cells	Zhanqi Dong
APCMV1273	Functional Characterisation of O'nyong'nyong Virus-Specific Neutralising Monoclonal Antibodies	Vanessa Neo
APCMV1283	Unlocking the Secrets of Mosquito Saliva: Investigating Immune Modulation During Mosquito-Borne Virus Infections	Siew-Wai Fong

ACCEPTED POSTER PRESENTATIONS

PLEASE CLICK HERE TO VIEW THE ACCEPTED POSTER SUBMISSIONS

Abstract No.	Topic Title	Full Name
APCMVE012	Development of Live-Attenuated Vaccines for Chikungunya Virus: A Study on Pathogenicity and Immunogenicity	Fumiyo Ogawa
APCMVE013	Tetravalent Microprojection-Based Dengue Chimeric Virus Vaccine Raises Potent Neutralising Antibodies in Mice	Jovin Choo Jia Ying
VIRAL DIAGNOSTICS		
APCMV1109	Comparative Evaluation of Two Commercial Assays- Chromatographic Immunoassay Vs Qualitative Multiplex PCR for Detection of Viral Pathogens in Stool Samples At a Cancer Set Up	Sujata Lall
APCMV1138	Pre-COVID-19 Paediatric Face-Mask Sampling of Seasonal Respiratory Viruses	Julian Wei-Tze Tang
APCMV1253	Diagnosis of Herpes Simplex Virus Infections in the Clinical Laboratory by PCR: An Observational Study Done In Zoram Medical College, Mizoram, India	Lalrinpari Sailo
BLOOD BORNE VIRUSES		
APCMV1134	Galectin-3 Regulates Viral Pathogenesis and Inflammation in H5N1 and H7N9 Avian Influenza Virus Infections	Zih Syuan Yang
APCMV1135	Genetic Insights into HBV S Gene Mutations, Genotypes and Subtypes in HBV-HIV Co-Infected Viz a Viz HBV Mono-Infected Patients: An Observational Study from North India	Hiba Sami
APCMV1182	10 Years (2015-2024) of Hepatitis C Drug Resistance Mutations in the Era of Directly Acting Antiviral Therapy	Julian Wei-Tze Tang
APCMV1266	Identification of Novel Diarylpyrimidine Derivatives as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors by Exploring Solvent-Exposed Region	Jiang Xiangyi
APCMVE009	APOBEC3 is the Primary Target of HIV-1 Vif to Produce Infectious Virions in Myeloid Cell Line THP-1 Under Type I Interferon Treatment	Michael Jonathan
OTHER VIRUS INFECTIONS		
APCMV1053	Non-Polio Enterovirus Infections in Children and Neonates Presenting to Hospital Requiring Lumbar Puncture In Leicester, United Kingdom 2019-2023: Serotypes And Clinical Characteristics	Julian Wei-Tze Tang
APCMV1091	Cluster of Acute Parvovirus B19 Cases Dec 2023-May 2024, Leicester, UK – Possible Post-COVID-19 Phenomenon?	Julian Wei-Tze Tang
APCMV1202	Improving Prognosis Through Early Diagnosis: Neonatal Herpetic Keratoconjunctivitis	Hui Shan Chua
APCMV1203	Identifying Gaps in Congenital CMV Detection at A Single Site, Tertiary Hospital, Leicester UK	Julian Wei-Tze Tang

ACCEPTED POSTER PRESENTATIONS

PLEASE CLICK HERE TO VIEW THE ACCEPTED POSTER SUBMISSIONS

Abstract No.	Topic Title	Full Name
APCMV1260	Concurrent Cytomegalovirus Retinitis and Neurosyphilis Both Presenting as Bilateral Optic Neuritis in a Patient with HIV: A Case Report	Rafshanjani Adil
PREVENTION AND CONTROL OF VIRAL INFECTIONS		
APCMV1010	Clinical Analysis of Reinfection/Newly Infected HCV Infection in Long-Term Treatment of HIV/AIDS Patients	Yun He
APCMV1011	Tanomastat Exerts Multi-Targeted Inhibitory Effects on Viral Capsid Dissociation and RNA Replication in Human Enteroviruses	Therese Lim
APCMV1042	WW Domain-Containing Oxidoreductase Functions as A Novel IRES Trans-Acting Factor for Suppressing Enterovirus A71 Initial Translation in Host Cells	Wei Chiang
APCMV1046	Mitochondrial Uncouplers as A Broad-Spectrum Antiviral Agent	Kunlakanya Jitobaom
APCMV1080	Novel Antiviral Strategies: Veratides and Antibody Fusions Overcome Therapeutic Challenges and Improve Efficacy	Hyunjin Jeon
APCMV1082	Repeated Exposure to SARS-CoV-2 Antigens Induces Exceptionally Broad and Potent Neutralising Immunity to Major Sarbecoviruses in Humans Including SARS-CoV-1	Peng Chen
APCMV1141	Synergistic Antiviral Effect of Positively Surface-Charged Silver Nanoparticles with Oseltamivir Against Influenza a Viruses at Biocompatible Dosage	Ping Cheng Liu
APCMV1186	Unveiling MARVAS213: A Novel Antiviral for Enterovirus RNA Replication Discovered Via Protein Interaction Screening	Yuhui Deborah Fong
APCMV1188	Deciphering Enterovirus D68 Antiviral Mechanisms	Khoo Xuan Wei
APCMV1209	CRISPR/Cas9-Generated CTL16 Knockout in Aedes Aegypti Reveals Impact on DENV Replication and IMD And JAK/STAT Immune Signalling	Wei-Liang Liu
APCMV1212	Role of the Structural Region P1 in Enterovirus-A71 Fitness and Virulence	Kai Hui Clarissa Tan
APCMV1226	Study on the Seroepidemiology of Japanese Encephalitis in Tainan, Taiwan	Ya Fang Wang
APCMV1272	Targeting Chemokine Receptors with the ML/AI Web Service GPCRVS for GPCR Virtual Screening	Dorota Latek
APCMV1048	Therapeutic Potential of an Anti-Gn Glycoprotein Antibody Against Severe Fever with Thrombocytopenia Syndrome Virus Infection in A129 Mice	Jinah Lee
APCMV1019	Increased Prevalence of Human Astrovirus Type 1 Infection in the Summer of 2022: An 8-Year Analysis	Hyun Soo Kim

ACCEPTED POSTER PRESENTATIONS

PLEASE CLICK HERE TO VIEW THE ACCEPTED POSTER SUBMISSIONS

Abstract No.	Topic Title	Full Name
APCMV1030	Integrated Approach for Real-Time Detection and Mitigation of Airborne Coronaviruses in Indoor Environments	Katheresan Selvam Sooriya Kannan
APCMV1071	Emerging Viral Infectious Disease Awareness Using Minion Sequencing at Indonesian Animal Markets	Callum Le Lay
VIRUS SURVEILLANCE AND PUBLIC HEALTH INTERVENTION		
APCMV1076	Low False-Recent Rate of the HIV-1 Rapid Test for Recent Infection in Detecting Long-Standing HIV Infection	Supaporn Suparak
APCMV1146	Molecular Analysis of Mpox Genomes from Patients in Central Thailand Suggests the Circulation of Multiple Sub-Lineages, 2023	Spencer Sterling
APCMV1152	The Disease Risks and Vaccine Gaps of Known Betacoronaviruses and Henipaviruses	Beng Lee Lim
APCMV1162	SARS-CoV-2 Variants Genetic Profile Under Immune Selection in Healthy and Immunocompromised Individuals in Vitro	Jolene Fu
APCMV1173	Novel Intertypic Recombinant Coxsackievirus A2 with Specific Amino Acid Mutations in the RNA-Dependent RNA Polymerase Potentially Associated with Its Emergence	Zhenfeng Xie
APCMV1180	Association of COVID-19 with Short- and Long-Term Risk of Cardiovascular Disease and Mortality: A Prospective Cohort in UK Biobank	Sukriti Mathur
APCMV1192	Factors Affecting Differences in East-West Pandemic Responses	Julian Wei-Tze Tang
APCMV1257	Post-Pandemic Enterovirus Epidemiology and Evolution in Northern Taiwan	Lin Ya-Jhu
APCMV1258	COVID-19 Molecular Surveillance in Taiwan	Tzu-Hsuan Hsieh
APCMV1264	Investigating the Evolution of Seasonal Human Coronaviruses and Their Application to Future Evolutionary Directions of SARS-CoV-2	Hannah Goldswain

EXHIBITORS

ABB Robotics as one of the world's leading robotics suppliers, is the only company with a comprehensive and integrated portfolio covering robots and Autonomous Mobile Robots solutions, designed and orchestrated by our value-creating software. We help companies of all sizes and sectors – from automotive to electronics and logistics – become more resilient, flexible and efficient. ABB Robotics supports customers in the transition towards the connected and collaborative factory of the future. The business area employs approximately 11,000 people at over 100 locations in approximately 53 countries.

CorDx is transforming the global diagnostics industry with innovative R&D solutions, a vertically integrated supply chain, and manufacturing footprints in the United States and around the world.

With nearly two decades of IVD experience, CorDx is a leader in IVD research and development, manufacturing, and supply chain. Our proprietary line of rapid diagnostic products is recognized by families and medical professionals for reliability, affordability, and rapid results.

Eppendorf is a leading life science company that develops and sells instruments, consumables and services for liquid, sample and cell handling in laboratories worldwide. Divided into the business units Liquid Handling, Consumables, Separation & Instrumentation and Bioprocess, the product portfolio includes, for example, pipettes, pipette tips, centrifuges, mixers and ultra-low temperature equipment. Eppendorf products are most broadly used in academic and commercial research laboratories, e.g., in companies from the pharmaceutical and biotechnological as well as the chemical and food industries.

This year, Eppendorf is celebrating 60 years since the first microcentrifuge at Eppendorf completed the famous microlitre system. Since 1964, Eppendorf has been developing, producing, and distributing high-quality centrifuges for you with user-friendliness, quality, and longevity as guiding principles. Our goal is to provide optimized solutions for you and your requirements: From microcentrifuges and benchtop centrifuges to high-speed floorstanding- as well as ultracentrifuges, our extensive portfolio offers comprehensive solutions in the areas of molecular biology, biochemistry and cell biology.

With our now complete centrifuge portfolio we give you the promise of separation at ease, enabling you to focus on what matters most: "Your Research".

EXHIBITORS

Gaia Science

Founded in Singapore on September 7th, 2009, and headquartered at 102E Pasir Panjang Road #02-07 Singapore 118529, Gaia Science Pte Ltd has emerged as a growing employee-owned enterprise that effectively synergizes the collective strengths of dedicated individuals who share a common vision: to drive the company's expansion through collaborative initiatives for the advancement of science and a better world.

Our dedicated team is composed of life science professionals possessing extensive expertise within the scientific industry. Our specialization lies in furnishing universities, research institutions, hospitals, and various other industries with cutting-edge scientific and laboratory solutions.

Renowned as facilitators of state-of-the-art technologies and solutions sourced from our partner firms to our esteemed clients, we unwaveringly strive to uphold this distinguished reputation.

Website: www.gaiascience.com.sg
Contact No.: +65 6897 2772
Email: enquiry@gaiascience.com.sg

GCCS
GLOBAL COLD CHAIN SOLUTIONS
Specialty Courier Service | Healthcare & Life Sciences

Global Cold Chain Solutions (GCCS), your trusted Specialty Courier for Temperature-controlled logistics in the Biopharma, Healthcare and Life Sciences industry.

Leave the complexity and challenges of temperature-controlled logistics to Global Cold Chain Solutions, from pre-shipment documentation checks, proposal of suitable packaging solutions and, pro-active shipment monitoring to ensure timely delivery of your items.

Regardless of temperature, shipping in Dry Ice at negative 80degC, Liquid Nitrogen at negative 180degC, Refrigerated at +2 to +8 degC or Controlled Ambient at +15 to +25 degC, our team understands the importance of temperature control to maintain the integrity and viability of your items.

Whether shipping Research samples, Clinical Trials samples, Investigational Drugs, Active Pharmaceutical Ingredients (API), Live Laboratory Animals or providing customs regulatory advice, our team is committed to deliver.

At Global Cold Chain Solutions (GCCS), we strive to be your trusted Temperature-controlled logistics partner.

Our clients' success stories speak volumes. Partner with us for your success story.

Email us at sincs@gccscourier.com or contact us at Tel: +65 6246 4385
Visit our website www.globalcoldchainsolutionsg.com or LinkedIn Global Cold Chain Solutions

EXHIBITORS

MDPI
Academic Open Access Publishing
since 1996

A pioneer in scholarly, open access publishing, MDPI has supported academic communities since 1996. Based in Basel, Switzerland, MDPI has the mission to foster open scientific exchange in all forms, across all disciplines.

Our 448 diverse and open access journals, including 439 peer-reviewed journals and 9 conference journals, are supported by more than 295,000 academic experts who share our mission, values, and commitment to providing high-quality service for our authors. We serve scholars from around the world to ensure the latest research is freely available and all content is distributed under a Creative Commons Attribution License (CC BY).

MDPI publishes over 98 journals that are ranked as high impact within their fields. To view the current impact factors for MDPI journals (according to the Journal Citation Reports), please visit our yearly announcement page here. With additional offices in Beijing, Wuhan, Tianjin and Nanjing (China), Barcelona (Spain), Belgrade and Novi Sad (Serbia), Manchester (UK), Tokyo (Japan), Cluj and Bucharest (Romania), Toronto (Canada), Kraków (Poland), Singapore (Singapore), Bangkok (Thailand) and Seoul (Republic of Korea), MDPI has published the research of more than 330,000 individual authors and our journals receive more than 25 million monthly webpage views.

Precision Technologies' Scientific & Biomedical Business Unit provides advanced equipment, reagents, and molecular diagnostics solutions for hospitals, research institutions, and biotech companies. Our offerings include molecular and biological reagents, tools for animal and human research, DNA sequencing, NGS, and imaging solutions. We specialize in preclinical research, genomics, microbiology, oncology, and infectious diseases, with a focus on delivering comprehensive application and technical support. In partnership with world-renowned providers, we ensure top-quality solutions for your research needs.

Contact us:

Email: scitech@pretech.com.sg
Phone: +65 6273 4573

EXHIBITORS

Promega

As a leader in life sciences with a portfolio of over 4,000 products, Promega offers innovative solutions that empower researchers to delve into viral dynamics, understand host-virus interactions, and elucidate immune responses critical for viral research and vaccine development. Our extensive portfolio includes advanced assays for SARS-CoV-2 research, bioluminescence-based methods for highly sensitive detection of cellular events such as viral entry and proliferation, and pioneering technologies like NanoBiT® and NanoBRET™, designed for in-depth viral:host protein interaction analysis.

Promega provides essential molecular biology reagents for detecting viral genomes and replication, including nucleic acid extraction kits, sequencing reagents, and PCR systems. Luminescence technologies such as firefly and NanoLuc® luciferase reporters, alongside the HiBiT protein tagging and detection system, have become invaluable in studying viral diseases due to their small size and sensitivity for detecting viral activity in cells and organisms. Viability and cytotoxicity cell health assays are used to support studies investigating the mechanism of action of viruses, including screening compounds for antiviral activity, or testing for viral-induced cytopathic effects (CPE) in host cells.

At the heart of Promega is our commitment to empowering scientists worldwide with the tools they need for groundbreaking virology and immunology research. We're here to support scientists in their journey in advancing viral studies and tackling viral diseases head-on.

SingLabs® altivolus una

Singlab Technologies Pte Ltd is a specialist distributor of instruments, research standards and services to the Singapore Life Science, Biotech and Biomedical Industry. We have more than 25 years domain experience, allowing us a better understanding of our customers' requirements. We help our customers by updating them on new products & technologies, and highlighting how these may aid and accelerate their processes, research & development workflows. We also support our suppliers with a knowledge-based sales, marketing and distribution services. We partner with our suppliers to serve the growing needs of our customers.

EXHIBITORS

Vazyme

Vazyme is a global supplier dedicated to the design, manufacture and application of bioactive proteins and continuously expands the application fields of core technologies in life science, in vitro diagnostics, bio-medicine, and exploratory business.

Yakult

Yakult first made its debut in Singapore in 1979, following the establishment of Yakult Singapore in 1978. What began as a modest operation in three small containers at Hillview Avenue has evolved into a thriving enterprise, now anchored in a state-of-the-art, multi-million-dollar facility at Senoko Avenue.

The journey from these humble beginnings to our cutting-edge plant reflects Yakult's unwavering commitment to quality and innovation. Our local production ensures that every bottle of Yakult sold in Singapore meets the highest standards of freshness and excellence. By manufacturing right here in Singapore, we are able to provide our customers with the premium quality that they have come to trust and expect.

Yakult Singapore is dedicated to promoting a healthy lifestyle across the nation. We are passionate about sharing the benefits of our unique probiotic strain, L. paracasei strain Shirota, which is the cornerstone of our product. This specific probiotic strain, known for its numerous health benefits, has been central to our mission since the inception of our company.

Our commitment extends beyond just the product. We adhere to the principles of Shirota-ism, a philosophy rooted in the belief that improving the health of individuals leads to a healthier society as a whole. This guiding principle drives us to continually educate and inspire the people of Singapore about the advantages of incorporating Yakult into their daily routines.

By staying true to these values, Yakult Singapore not only strives to enhance individual well-being but also aims to contribute to the overall health of the community. As we continue our journey, we are excited to spread the message of health and vitality, ensuring that everyone in Singapore can experience the benefits of our probiotic drink and live a healthier life.